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Abstract
Background: This study aims to estimate the age-specific risks of clinical dengue attack (i.e., the risk of symptomatic dengue
among the total number of dengue virus (DENV) infections) during primary and secondary infections.
Methods: We analyzed two pieces of epidemiological information in Binh Thuan province, southern Vietnam, i.e., age-
specific seroprevalence and a community-wide longitudinal study of clinical dengue attack. The latter data set stratified
febrile patients with DENV infection by age as well as infection parity. A simple modeling approach was employed to
estimate the age-specific risks of clinical dengue attack during primary and secondary infections.
Results: Using the seroprevalence data, the force of infection was estimated to be 11.7% (95% confidence intervals (CI):
10.8–12.7) per year. Median age (and the 25–75 percentiles) of dengue fever patients during primary and secondary
infections were 12 (9–20) and 20 (14–31) years, respectively. The estimated age-specific risk of clinical dengue increases as a
function of age for both primary and secondary infections; the estimated proportion of symptomatic patients among the
total number of infected individuals was estimated to be ,7% for those aged ,10 years for both primary and secondary
infections, but increased as patients become older, reaching to 8–11% by the age of 20 years.
Conclusions/Significance: For both primary and secondary infections, higher age at DENV infection was shown to result in
higher risk of clinical attack. Age as an important modulator of clinical dengue explains recent increase in dengue
notifications in ageing countries in Southeast Asia, and moreover, poses a paradoxical problem of an increase in adult
patients resulting from a decline in the force of infection, which may be caused by various factors including time-dependent
variations in epidemiological, ecological and demographic dynamics.
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Introduction
Dengue ranks among the most important infectious diseases
with a major impact on public health in many countries in the
tropics and subtropics. Estimates showed that approximately 3.5
billion people, ,55% of the world’s population live in countries at
risk for dengue [1]. The global incidence has increased steadily
over the last six decades, simultaneously with an increase in
geographic distribution and a transition from epidemic-type
dengue with long interepidemic intervals to endemic-type with
seasonal fluctuation [2–4].
Dengue virus (DENV) transmission primarily takes place
through bites by the principal mosquito vectors, Aedes aegypti,
which feed preferentially on human blood, and are often found in
and around human dwellings [5,6]. Infection with any of the four
dengue serotypes results in either asymptomatic infection, or a
spectrum of clinically apparent disease ranging from mild
undifferentiated febrile illness to severe dengue of which dengue
shock syndrome (DSS) is the most common life threatening
syndrome in children [7]. The mechanisms for the variable clinical
outcome are not completely elucidated, but genetic factors, race,
maternal antibody, circulating serotype and infection with
multiple serotypes are believed to play an important role in
determining the disease severity [8].
When it comes to the disease severity, a well-established
epidemiological risk factor is the age at infection [9–12]. It is
known that differences in clinically apparent dengue vary by age;
pre-school children and infants have rather more often undiffer-
entiated febrile illnesses while pre-adolescent children often
develop fever [13], and moreover younger children with dengue
hemorrhagic fever (DHF) are known to experience more severe
clinical outcome (e.g. higher case fatality ratio) than adults [12].
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Singapore. A rigorous vector control program has substantially
reduced the transmission in Singapore and, as a consequence,
dengue patients are predominantly seen in adults. Nevertheless,
with the elevation in patients’ age, the outcome of DENV infection
may be more favorable since most adult dengue patients present
with dengue fever (DF) instead of with DHF [14].
Apart from age, infection parity is known to be a critical factor
of disease severity; primary infection with any of the four serotypes
is believed to elicit lifelong immunity against that serotype, but
confers partial or transient immunity against other serotypes
[15,16]. Cross-reactive, but sub-neutralizing DENV-reactive IgG,
acquired by a previous heterotypic serotype infection may enhance
DENV infectivity which may result in higher viral burden and
contribute to induced disease severity. Heterologous secondary
infections have been associated with large, clinical outbreaks of
DHF/DSS where severe dengue occurs most frequently in
children [12]. In some rigorous observations, the age group with
highest susceptibility to contracting DSS was that of children with
a modal age of 8 to 11 years [17,18].
Although age at infection and infection parity are the
representative key modulators of clinical dengue and disease
severity, their relationship has yet to be established and explicitly
quantified. A previous study investigated the relationship between
age at primary infection in Brazil and the risk of febrile illness,
suggesting that adults are more likely than children to have clinical
dengue [19]. This result should ideally be validated in the
Southeast Asian settings. Moreover, we have yet to understand the
age-specific risk of symptomatic disease during secondary
infection. This present study tackles these issues by analyzing
epidemiological data sets in southern Vietnam, focusing specifi-
cally on the age-specific risk of symptomatic dengue given
infection. That is, we do not consider age-specific severity of
clinical dengue, and rather, focusing only on the conditional
probability of illness given infection. Because of high transmission
potential with co-circulating multiple serotypes, dengue has been
mainly a pediatric disease in Vietnam, and ironically, this provides
us with an opportunity to investigate the age-specific risks of
clinical attack both during primary and secondary infections. The
present study aims to characterize a fundamental relationship
between age at DENV infection and the risk of developing clinical
attack.
Methods
Ethics statement
The protocols for recruitment, testing and follow-up were
approved by the Review Board of the Cho Ray Hospital, Ho Chi
Minh City, Provincial Health Services and the community
stations. The study was explained and discussed in meetings
(e.g. with the People’s Committee of the communities, the PHC-
staff and school teachers). All patients (or, for children, the parents
or guardian) gave written informed consent.
Study site
Our study rests on empirical observations in Binh Thuan
province which is located along the south-eastern coast of
Vietnam, 150 km northeast of Ho Chi Minh City, wedged
between the Truong Son forested mountains (alt. 1100–1642 m) in
the west and the South Chinese Sea in the east. It covers
7,828 km
2 and the estimated population was 1,140,429 inhabi-
tants in 2004. The majority of the population lives in rural areas,
with approximately 187,042 people in and around the capital,
Phan Thiet City. Healthcare is provided by a provincial hospital in
Phan Thiet city, nine district hospitals and 115 community posts
for primary healthcare (PHC) and disease control.
Epidemiological data
We examined two pieces of epidemiological information, (i) age-
specific seroprevalence and (ii) age-specific frequency of clinical
attack of dengue during primary and secondary infections, as
determined by serological confirmation, in order to estimate the
age-specific risk of clinical dengue attack. Figure S1 shows the
participating PHCs and the villages in which the serosurvey were
conducted. The mean distance between the source of seroprev-
alence data and all PHCs was 40.5 km (range 3–87 km).
The former data set included age stratified seroprevalence data
from a cross-sectional survey among primary school children in
two communities (Ham Kiem and Ham Hiep). This survey was
conducted among 961 children, aged from 7 to 14 years, in 2003.
The detailed results are given elsewhere [20,21]. Approximately
1 ml of blood was collected by finger puncture in plain vials
(Greiner, Minicollect), left to clot at ambient temperature,
centrifuged at 1000 rpm for 15 minutes and serum was transferred
to a sterile vial for storage at 220uC until testing. All samples were
tested for the presence of dengue specific serum antibodies against
dengue virus using a commercial available indirect IgG enzyme-
linked immunosorbent assay (ELISA). The indirect IgG ELISA
was performed according to the manufactures instructions (Focus
Technologies Inc., Cypress, CA, USA) [22]. Optical density (OD)
values were measured at 450 nm with 620 nm as a reference with
a Benchmark microplate reader (Bio-Rad Laboratories, Inc.,
Hercules, CA, USA). Results were expressed as the ratio between
the sample OD value and the OD value of the kit calibration
serum (ODR), both after subtraction of the OD of an enclosed
blank specimen. ODR values .1 were considered positive.
Seroprevalence (i.e. proportion positive) was stratified by age
group.
Author Summary
Although age at dengue virus (DENV) infection is
recognized as playing a key role in characterizing the risks
of clinical attack and disease severity, the contributions of
age to disease development have yet to be quantified in
detail. We estimated the age-specific risk of clinical attack
(i.e., the risk of symptomatic dengue among the total
number of DENV infections) during primary and secondary
DENV infections in Vietnam, by employing a simple
epidemiological modeling approach in which two pieces
of epidemiological data sets were used, i.e., (i) age-specific
seroprevalence and (ii) age-specific frequency of clinical
attack of dengue during primary and secondary infections.
We showed that those at higher age are more likely to
develop symptomatic dengue than younger individuals for
both primary and secondary infections; the estimated
proportion of symptomatic patients among the total
number of infected individuals was below 7% for those
aged younger than 10 years of age for both primary and
secondary infections, but was shown to be elevated as the
patients become older, reaching to 8–11% by the age of
20 years. Age as an important modulator of clinical dengue
attack explains recent increase in dengue notifications in
ageing countries in Southeast Asia, and moreover, poses a
paradoxical problem of an increase in adult patients
resulting from a decline in the force of infection, which
may be caused by various factors including time-depen-
dent variations in epidemiological, ecological and demo-
graphic dynamics.
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from a prospective longitudinal observational study at 12 PHCs
across Binh Thuan province and at the provincial malaria control
center in Phan Thiet City. That study examined the etiology of
acute undifferentiated fever (AUF) from March 2001 to March
2006 [23–27]. All patients presenting with AUF were included.
AUF was defined as any febrile illness of duration less than 14
days, confirmed by an axillary temperature of $38.0uC, without
any clinical indication for either severe systemic or organ specific
disease. Malaria was excluded by microscopic examination of a
thick blood smear. A standardized questionnaire was employed to
collect demographic and clinical information. Serum samples were
collected from patients with a febrile illness by venous puncture on
presentation (acute sample; t0) and after 3 weeks (convalescence
sample; t3). Serum samples were stored at 220uC at the study sites
until monthly transfer to Cho Ray hospital (Ho Chi Minh City,
Vietnam), where they were stored at 270uC. Complete sets of
acute and convalescence samples were selected for dengue
serology. In 2001 all collected serum pairs were tested with
dengue ELISA; afterwards paired samples were randomly selected
as two patients per PHC and per month from the total data set
[23]. Paired serum samples were tested for dengue with direct IgG
ELISA and IgM-Capture ELISA (Focus Technologies Inc.,
Cypress, CA, USA). It should be noted that these serological tests
did not distinguish between an infection with DENV from that
with Japanese Encephalitis virus (JEV). Cross-reactivity with JEV
antibodies may have occurred, potentially involving a small
proportion of samples [21]. Details regarding the ELISA and the
interpretation of results were described previously [28]. In brief, a
fourfold increase of antibody concentrations between t0 and t3 was
considered significant. The IgM concentration on t3, relative to
the IgG concentration on t3 was also used as a criterion. Acute
primary DENV infection was defined as positive IgM on t3 with
an IgM/IgG ratio on t3 greater than one. A positive IgM on t3
with an IgM/IgG ratio on t3 less than one, or a negative IgM
reaction on t3 but with a positive IgG t3 and a fourfold molar
increase of IgG between t0 to t3 were classified as acute secondary
dengue. A negative IgM reaction on t3, a positive IgG on t3 but
without a fourfold increase between t0 and t3 was classified as ‘‘not
acute dengue but past infection’’, and a subject of both negative
IgM and IgG on t3 was classified as ‘‘no dengue’’. It could well be
possible that patients with an immune response to secondary
dengue infection have had a tertiary or even dengue infection with
a fourth serotype. Because the immune response between
sequential dengue infections was not explicitly distinguished by
using this ELISA, we grouped all individuals with serological
indicative of a repeated infection and defined these as the
secondary dengue infections in the present study. The epidemi-
ological, virological and clinical features have been described
elsewhere [29]. All four serotypes have been circulating during the
study period with a potential shift of the dominant DENV serotype
over time. Whereas DENV-4 was the dominant serotype in 2001–
2002, DENV-1 and DENV-2 later came to be most frequently
isolated.
Mathematical model and statistical estimation
Sequential transmission dynamics of DENV infection.
A simple epidemiological model was developed to estimate the
age-specific risks of clinical dengue attack during primary and
secondary infections. The model was constructed to describe the
age-specific frequencies of primary and secondary infections
(which were used as the denominator population, representing
infected individuals), and we combine it with our empirical data of
the age-specific frequencies of individuals with symptomatic
dengue during primary and secondary infections (which were
dealt with as the numerator population, representing symptomatic
dengue patients) in order to estimate the age-specific conditional
risk of clinical dengue attack (given infection). Figure 1 illustrates
the compartments of our model, describing the lifetime risks of
primary, secondary and tertiary infections. The model accounts
for the age-specificity of infection and acquisition of serotype-
specific immunity over lifetime. Similar sequential assumptions
have been employed in previous studies [30–33]. The
mathematical descriptions are given in Text S1. Among the
parameters in Figure 1, we estimate the force of infection (i.e., the
rate at which susceptible individuals get infected), l, from
seroprevalence data, and the remaining parameters, i.e., the
scaling factor representing the number of co-circulating serotypes
(a) and the loss rate of cross-protective immunity (d), were assumed
known. All four serotypes have been observed in Binh Thuan
province, but the relative frequency of serotype 3 has been smaller
than other serotypes [29,34]. Because of the irregularity in the
serotype-specific frequency, which yields variations in the
transmission potential between different serotypes, we therefore
varied a from 2.5 to 4.0 with a default value 3.5. The duration of
cross-protective immunity in literature ranges from 1–2 weeks [35]
to 2–9 months [36]. Although not based on an explicit statistical
estimation, the latter study suggested that within 2 months after a
primary attack offered full protection, and that within 9 months
after the primary attack may still yield partial protective immunity
to infection with heterologous strain (e.g. partial reductions in
clinical symptoms) [36]. Accordingly, we varied d from 10 days to
Figure 1. Sequential transmission dynamics of DENV infection. Each compartment represents an age-specific state of DENV infection. Si(a)i s
theproportion ofsusceptibleindividualswho areatriskofinfectionbytheserotypesthatremain(a-i) afterpreviousinfectionsatage a(fori=0,1 and2).
Ii(a) represents the proportion of those who have experienced infections with i-th serotype and remain still protected against the remaining
heterologous serotypesdueto short-lived cross-protective immunity. At age 0, S0(0)=1 andother compartments are0. l is the force of infection, i.e.the
rate at which susceptible individuals experience infection, for a single serotype. a is a scaling factor which can be interpreted as the number of
co-circulating serotypes. We assume that human hosts experience an identical risk of infection between heterologous serotypes. d is the rate at which
cross-protective immunity against remaining heterologous serotypes declines. Infection with a fourth serotype is ignored, because it is very uncommon.
doi:10.1371/journal.pntd.0001180.g001
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information, we ignored potential variations in virulence between
strains (see Discussion). The following assumptions were made to
attain a simple statistical estimation; (i) the force of infection, l,
was age-independent (and we focused on relatively young age
groups in the population), (ii) the transmission intensities has
reached to an endemic equilibrium so that the time-
inhomogeneity can be ignored (as we focused on the data sets
covering a short period of time), (iii) the transmission potential is
identical among co-circulating serotypes (though we accounted for
non-integer values for a as a theoretical adjustment), (iv) once an
individual acquires infection with a single serotype, he/she
becomes temporarily immune against infection with other
heterologous serotypes (which is lost at a rate d) and
permanently immune against further infections with the identical
serotype and (v) our empirical data represent the transmission
dynamics for the entire population of Binh Thuan province.
Although omitted from Figure 1 for simplicity, the natural death
rate, m (per year), occurs in each compartment. We obtained the
population data from the Binh Thuan statistics office, Phan Thiet
City, southern Vietnam, and estimated m, assuming that the
population is stable and also that the survivorship in this rural
population is sufficiently approximated by an exponential
distribution.
The age-specific proportion of those having experienced
infection at least with one serotype is given by 12exp(2ala),
and the age-specific survivorship at age a is written as exp(2ma).
Supposing that there were na seropositive and ma seronegative
results at age a, the likelihood function to estimate l is
L(l)~P
a
(1{exp({ala))
na exp({ala)
ma: ð1Þ
Exactly the same argument was made to estimate m.
Estimation of the age-specific risk of clinical
attack. Subsequently, we estimated the age-specific risks of
clinical attack during primary and secondary infections, r1(a) and
r2(a), respectively. Let S0(a), S1(a) and S2(a) be the expected
proportions of susceptible individuals (among a total population),
based on our model, who are susceptible to the remaining a, a21
and a22 serotypes at age a, respectively. The incidence of
primary, secondary and tertiary infections at age a are then given
by alS0(a), (a21)lS1(a) and (a22)lS2(a), respectively. We ignored
infection with fourth serotype assuming that it is rare, and we
grouped the incidence of secondary and tertiary infections to
adhere to our empirical observation of secondary infections in the
longitudinal survey (and assumed that the risk of clinical attack
between secondary and tertiary infections is identical).
Accordingly, r1(a) and r2(a) were, respectively, conditioned on
primary infection and secondary and tertiary infections. Observing
a signature of an increase in r1(a) and r2(a) as a function of age in
the empirical data, three statistical models, logit (l), Weibull (w) and
exponential (e) distributions, were employed for these functions,
i.e.,
ri,l(a)~
kp0 exp(ra)
kzp0(exp(ra){1)
,
ri,w(a)~1{exp({kar),
ri,e(a)~1{exp({ka),
ð2Þ
for i=1 or 2, where k, p0 and r are the parameters. Given a data
set of n patients during primary infection and m patients during
secondary infection with their age at infection ai, the likelihood
function to estimate parameters for r1(a) and r2(a)i s
L(hjai,a,l,d)~ P
n
i~1
r1,q(ai)S0(ai)
Ð ?
0 r1,q(a)S0(a)da
P
m
i~1
r1,q(ai)( a{1)lS1(ai)z(a{2)lS2(ai) ½ 
Ð ?
0 r1,q(a)( a{1)lS1(a)z(a{2)lS2(a) ½  da
ð3Þ
for q=l, w or e. It should be noted that Si(a) were solved
analytically and replaced by parameters m, l, a and d (see Text
S1). Maximum likelihood estimates of the parameters were
obtained by minimizing negative logarithm of (3). The lack-of-fit
of three parametric models were compared by employing Akaike
information criterion (AIC).
Results
Demography and the force of infection
The age-specific population size of Binh Thuan province is
shown in Figure 2A. Mean and median ages (and the 25–75
percentiles) were 24.7 and 20 (9–35) years, respectively. Employing
an exponential approximation, the natural death rate (m) was
estimated to be 4.05610
22 (95% confidence interval (CI):
4.04610
22–4.05610
22) per year. Figure 2B shows the observed
and predicted age-dependent seroprevalence. The force of
infection of the total of a serotypes, al, was estimated as 11.7%
(95% CI: 10.8–12.7) per year.
Symptomatic primary, secondary or tertiary dengue
infections
A total of 14595 febrile patients were included in our
longitudinal survey. Eighty-three patients were excluded as the
inclusion criteria for AUF were not met. That is, eleven patients
were afebrile (i.e. ,38uC), axillary temperatures of 19 patients
were not documented, and 53 patients were diagnosed with an
organ specific disease (e.g. pharyngitis) at presentation. Paired sera
were collected from 8268 febrile patients; 1938 (23.4%) serum
pairs were tested with dengue IgM- and IgG-ELISA. Of these,
DENV infection was serologically confirmed in 382 patients
(19.7%). Primary infection accounted for 76 confirmed patients
(19.9%), and secondary infection for 306 patients. Their age-
specific frequencies are shown in Figures 2C and 2D, respectively.
Median age (and the 25–75 percentiles) of dengue fever patients
during primary and secondary infections were 12 (9–20) and 20
(14–31) years, respectively, revealing that secondary infection
occurs at significantly older ages (p,0.01, Wilcoxon test). None of
confirmed dengue infections were suggestive of severe clinical
forms of dengue, DHF or DSS.
Epidemiological dynamics of dengue
Using the maximum likelihood estimate of al=0.117 and the
default values of a and d, age-specific frequencies of primary,
secondary and tertiary infections are shown in Figure 3A. As
indicated by 1/al, the mean age at primary infection is 8.5 years,
and secondary and tertiary infections occur at older ages. Figure 3B
shows the estimated risks of symptomatic dengue during primary
and secondary infections for Weibull and exponential assumptions
(results with logit model is not shown as it yielded the similar
qualitative pattern to Weibull). The conditional risks of clinical
attack were shown to increase as a function of age during both
primary and secondary infections. The estimated proportion of
symptomatic subjects among the total number of infected
individuals was below 7% for those aged younger than 10 years
of age for both primary and secondary infections, but increased as
Age-Specificity of Clinical Dengue
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Within the age-band examined (,60 years), both assumptions
indicate that the risk of symptomatic dengue during secondary
infection is higher than that during primary infection for all ages.
The Weibull distributed age-specific risk of clinical dengue during
primary and secondary infections plateau around the ages of 15
and 19 years, respectively. Figures 3C and 3D compares the
observed and predicted age-specific numbers of symptomatic
subjects during primary and secondary infections, respectively.
Using default values of a and d, the AIC values were estimated to
be 1461, 1460 and 1470 for logit, Weibull and exponential
assumptions, respectively. The preference of Weibull assumption
did not change when we varied a from 2.5 to 4.0 and d from 10
days to 12 months.
Figures 4A and 4B examine the univariate sensitivity of r2(a)t oa
for Weibull and exponential assumptions, respectively. The age-
specific risk of clinical attack was the highest for all ages with a=3,
but the overall difference in the conditional risk from those with
other a remained within 5% for Weibull assumption. The Weibull
assumption was always preferred in terms of AIC, but the difference
in AIC between the logit and Weibull models remained ,3 for the
rangeofathatweexamined.Similarly,Figures4Cand 4Dshowthe
univariate sensitivity of r2(a)t od for the Weibull and exponential
assumptions, respectively. The age-specific risk of symptomatic
secondary dengue infection with default d (1 month) yielded the
smallest estimates, but again the difference in the estimated risks of
clinical attack remained within 5% for Weibull assumption. Again,
AIC values indicated Weibull model as the best, but the differences
in AIC values between logit and Weibull models remained ,3 for
the whole range of d. Since our prospective study involved only 29
and 36 children aged 10 years or younger during primary and
secondary infections, respectively, we also examined the effect of
sample size on the age-specific conditional risk of illness given
infection. Even when the absolute numbers of children #10 years
was doubled, the qualitative patterns of risks (i.e. age-specific
increase in the risk of disease, and higher risk during secondary
infection than primary infection) remained the same. However, the
age at which the risk of symptomatic dengue is saturated with logit
and Weibull assumptions, was shifted to the left, approximately by
3–4 years younger as compared to the baseline. The AIC values
were estimated to be 1664, 1664 and 1686 for logit, Weibull and
exponential assumptions, respectively. These increases perhaps
reflect a mismatch of the estimated force of infection with the
incidence data.
Figure 2. Population and the epidemiological data of DENV infection in Binh Thuan province, southern Vietnam. (A) Age-specific
population size (circles). The continuous line shows the predicted age-distribution by employing an exponential distribution as the survivorship
function. (B) Age-specific seroprevalence against at least one serotype of dengue among those aged from 7–14 years (data source; [20]). The
continuous line shows the predicted proportion positive using the maximum likelihood estimate of the force of infection (i.e. 11.7% per year). (C& D)
Observed absolute numbers of clinical attack of dengue during (C) primary and (D) secondary or tertiary infections. We assume that D does not
include any symptomatic dengue subjects due to infection with fourth serotype.
doi:10.1371/journal.pntd.0001180.g002
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We estimated the age-specific risks of clinical dengue attack by
combining two epidemiological data sets, (i) age-specific seroprev-
alence and (ii) age-specific frequency of symptomatic dengue
during primary and secondary infections. The former data set was
used to reconstruct the age-specific frequencies of primary and
secondary infections (including those with and without symptoms),
and subsequently, by taking the age-specific ratio of the latter data
set to the reconstructed infection frequency with an aid of
modeling method, the age-specific conditional probability of
disease given infection was estimated. Although our model
required a number of simplifying assumptions, we have shown
unambiguously that the conditional risks of clinical attack
increased as a function of age for both primary and secondary
infections. Thus, higher age-groups, e.g., adolescents and young
adults are more likely to develop symptomatic dengue than
younger individuals, e.g., primary school children. Moreover,
Weibull model indicates that the age-specific risks of symptomatic
disease in adults both during primary and secondary infection
remain almost independent of age, perhaps reflecting greater
variations in age-specific susceptibility to symptomatic disease
among children and adolescents. To our knowledge, the present
study is the first to characterize the age-specific risk of developing
clinical attack during both primary and secondary dengue
infection by means of epidemiological modeling method. Whereas
the risk of severe complications given clinically apparent dengue
(e.g., the risk of hospitalization and the case fatality ratio) in
children is higher than in adults [12], the age-specific risk of
disease itself is the other way around and increases with age.
Although pathogenesis of DENV infection and its severe
complications involves many unanswered questions, and despite
their multifactoral nature, our study emphasizes a critical
importance of age as a key modulating factor of the risks of
clinical attack during primary and secondary infections. Two
important practical implications can be drawn from our results.
First, as was shown in a study in Thailand, a rapid demographic
transition has taken place in many Southeast Asian countries
where swift ageing, i.e., the shift of the age distribution of human
population toward older ages, has been observed [37]. Our results
support the notion of Cummings et al. [37] in that the ageing
society is truly at risk of increase in dengue incidence. Indeed, Binh
Figure 3. Epidemiological dynamics of dengue infection. (A) Age-specific frequency of primary (thin solid line), secondary (thick solid line) and
tertiary infections (dashed line). The frequencies are characterized by the force of infection, the mean duration of cross-protective immunity and the
number of co-circulating serotypes. (B) Age-specific probability of developing clinical attacks of dengue given primary (thick lines) and secondary or
tertiary infection (thin lines). The continuous lines represent the results employing Weibull model, while broken lines are the estimates based on
exponential model. (C & D) Comparisons between observed and expected age-specific numbers of clinical attacks during (C) primary and (D)
secondary or tertiary infections. Three different models, logit (thin continuous lines; k=0.200, p0=0.224610
23, r=0.971), Weibull (dashed lines;
k=0.259610
23, r=3.991) and exponential (thick continuous lines; k=0.324610
24) approaches were employed.
doi:10.1371/journal.pntd.0001180.g003
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which is slightly greater than a previous published estimate (e.g.
5.2–6.1 years in Rayong, Thailand, 1980 [31]), indicating that the
transmission is less intensive in Binh Thuan province in the 21st
century than in Thailand, 1980. Second, while the incidence in
Southeast Asian countries has been increasing [38–42], there has
been a decline in the force of infection, resulting in a shift in the
age distribution of DHF toward older age groups [33,37]. In
addition to ageing, the decline might have reflected various factors
including time-dependent variations in epidemiological, ecological
and demographic dynamics, e.g natural decline in the transmis-
sion, successful control of vectors and human migration. Our
exercise suggests that such a decline in the force of infection could
nevertheless result in an increase in older symptomatic individuals,
thereby resulting in a paradoxical increase in the total number of
symptomatic dengue patients (and thus, the incidence of
symptomatic dengue individuals for the entire population).
Although clinical outcome of severe DENV infection in adults
may be more favorable than in children, in terms of prognosis of
clinically apparent dengue [12,14], the incidence of symptomatic
cases may not decrease with a slight decline in the force of
infection. Clarification on the population impact of age-specific
risks of clinical attack on the total number of severe forms of
dengue is the subject of our future studies.
Despite our successful estimation of the age-specific risk of
clinical dengue attack, two limitations of the present study should
be noted. First, the majority of DENV infections remain
asymptomatic, and a very small amount of symptomatic patients
(,5%) results in severe disease [9]. Our longitudinal survey data
did not capture sub-clinical infections or very mild symptomatic
patients, implying that our estimate of the risk of clinical attack
may have been potentially underestimated. Nevertheless, our
survey did not select for specific signs and symptoms of dengue,
examining only AUF patients by laboratory testing, and thus, we
believe that the age distributions (Figures 2C and 2D) reflected
unbiased age-specific frequencies of all the symptomatic subjects
Figure 4. Sensitivity of the conditional risk of symptomatic dengue disease given infection to uncertain parameters. All panels
examine the age-specific risks of developing clinical attacks of dengue given secondary or tertiary infection. (A & C) Weibull model. (B & D) Exponential
model. A & B examines the sensitivity of the risk to different number of co-circulating serotypes (a, the range: 2.5 and 4.0). We assume that human hosts
experience an identical risk of infection between serotypes. The baseline value of a was set at 3.5. C & D examines the sensitivity of the probability to
different mean durations of cross-protective immunity following primary and secondary infections (1/d, the range: 10 days to 1 year). The duration of
cross-protection following primary infection was assumed as identical to that following secondary infection. The baseline value of 1/d was set at
1 month. Results from the logit model are not shown, because the qualitative patterns are similar to those of Weibull model. Also, the sensitivity of the
risk of symptomatic disease during primary infection is not shown, because the probability is not sensitive to variations in a and d.
doi:10.1371/journal.pntd.0001180.g004
Age-Specificity of Clinical Dengue
www.plosntds.org 7 June 2011 | Volume 5 | Issue 6 | e1180during primary and secondary infections. Second, we assumed
that the force of infection is time- and age-independent and the
transmission potential is identical among all co-circulating
serotypes. Ignorance on these realisms, e.g., seasonality, age-
dependency and decline in l over a long period of time, forces us
to accentuate the lack of precision in our estimates of r1(a) and r2(a).
For example, the lack of age-dependency may have led to slight
underestimation in r1(a) among small children and potentially an
overestimation for both r1(a) and r2(a) among adults. Besides,
whereas modeling approach such as ours certainly requires a
number of unrealistic assumptions, we believe that our conclusion
on the qualitative pattern, i.e., an increase in the risk of clinical
attack with age, remains intact.
Of course, various other pre-infection factors other than age
and infection parity contribute to the risk of disease severity,
including cross-protective immunity between serotypes, the
number of co-circulating serotypes and their pathogenicity
[40,43–49]. Indeed, our incidence data did not include any
DHF patients among a total of 306 symptomatic patients during
secondary infection. Although no direct comparison can be made,
this 0% is significantly smaller than that estimated in a prospective
study in Thailand [9]. Possible explanations are that (a) our
prospective study focused on the etiology of AUF, and the fraction
of patients with severe dengue manifestations (e.g. who may not
have presented at the PHCs or have sought care directly at higher
medical level) might have been potentially disregarded, (b) the
average age at infection in Binh Thuan province is higher than
that in Bangkok during 1980s, and secondary infection at higher
age can reduce the absolute number of DHF patients, and (c) not
only serotype but also different strains could yield differential
virulence given symptomatic infection. Moreover, molecular
epidemiological studies have demonstrated that long-term expan-
sion of dengue epidemic is regulated by selection-driven adaptive
evolution of DENV strains [50–52]. Since the absolute risk of
symptomatic infection is vulnerable to the virus (strain)-specific
virulence as well as our reliance on symptoms of patients and help
seeking behavior, the estimate of absolute risk could potentially
vary from one region to another. In that sense, our simple
approach is regarded as a first step to characterize the
epidemiological determinants of dengue in a rudimentary fashion,
and our study at least confirmed age-specific increase in the risk of
clinical dengue given infection, offering practically important
implications. Modeling with sequential infection assumption still
remains to be a common strategy to capture the serotypic
sequential infection mechanisms [31–33,49], and future incorpo-
ration of strain-specificity needs to account for strain specific
virulence as well as host-response (including cross immunity) to
each strain [53], which will be far more complex than the
simplistic sequential approach.
In conclusion, we examined the age-specific risks of clinical
attack during primary and secondary DENV infections in
Vietnam, showing that those at higher age-group are more likely
to develop symptomatic disease than younger individuals. Age as
an important modulator of clinical dengue attack explains recent
epidemiological shift in dengue notification in ageing countries in
Southeast Asia, and moreover, poses a paradoxical problem of an
increase in adult patients resulting from a decline in the force of
infection which may be caused by various factors including time-
dependent variations in epidemiological, ecological and demo-
graphic dynamics.
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